{
    "nctId": "NCT03620526",
    "officialTitle": "Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction - the ILO-HOPE Clinical Trial",
    "inclusionCriteria": "1. presence of typical HF symptoms and signs\n2. LV ejection fraction \u2265 50\n3. elevated levels of NT-proBNP (at least \\>125 pg/ml)\n4. echocardiographic structural (a left atrial volume index \\> 34 mL/m2 or a left ventricular mass index \u2265115 g/m2 for males and \u226595 g/m2 for females) or functional alterations (E/e'\u226513 and a mean e' septal and lateral wall \\< 9 cm/s).\n* Must have minimum age of 18 Years\n* Must have maximum age of 90 Years",
    "exclusionCriteria": "1. chronic renal failure (creatinine \\> 250 \u03bcmol/L)\n2. significant hepatic disease, significant coronary artery disease (CAD) (coronary artery stenosis \\>70% without intervention or positive stress test),\n3. secondary hypertension,\n4. pericardial disease\n5. significant valvular heart disease (\\>mild stenosis, \\>moderate regurgitation),\n6. active cancer,\n7. cor pulmonale\n8. congenital heart disease\n9. high-output heart failure\n10. subjects receiving long-term treatment with phosphodiesterase 5 in-hibitors\n11. chronic atrial fibrillation."
}